BBIO vs RNA
BBIO: BridgeBio translates genetic science into medicines for rare genetic diseases through a decentralized portfolio model, with an FDA-approved lead product in transthyretin amyloidosis and multiple late-stage programs approaching commercialization. RNA: Atrium is an early-stage biotech pioneering antibody-conjugated RNA therapeutics to treat rare genetic cardiomyopathies by silencing disease-driving genes in the heart.
Side-by-side fundamentals
| Metric | BBIO | RNA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $82.66 | $12.17 | |
| Market cap as of 2026-07-23 | $16.2B | $210M | |
| PEG as of 2026-07-23 | -3.61 | n/a | |
| Net margin as of 2026-07-23 | -124.4% | -172.9% | BBIO higher |
| Gross margin as of 2026-07-23 | +95.1% | n/a | |
| Operating margin as of 2026-07-23 | -90.5% | -174.9% | BBIO higher |
| ROE as of 2026-07-23 | -206.7% | -40.3% | RNA higher |
| ROA as of 2026-07-23 | -65.8% | -592.6% | BBIO higher |
| Debt / equity as of 2026-07-23 | 8.27 | 0.00 | RNA lower |
| Revenue growth (YoY) as of 2026-07-23 | +355.2% | +22.0% | BBIO higher |
| Revenue CAGR (3y) SEC XBRL | +86.3% | n/a | |
| Beta as of 2026-07-23 | 0.97 | 0.98 | |
| 1-year return as of 2026-07-22 close | +79.6% | -63.9% | BBIO higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.